Treanda can now be used in indolent NHL, which follows first approval in chronic lymphocytic leukemia.

FDA approved Cephalon’s drug Treanda for a second cancer indication: indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

In March Treanda was sanctioned for the treatment of chronic lymphocytic leukemia. Cephalon reported $24.6 million in sales for Treanda in the third quarter, up 71% from the prior quarter.

Cephalon’s pivotal trial involved 100 patients and demonstrated a high response rate to Treanda. Data showed Treanda as a single agent resulted in an overall response rate of 74%. Patient response to treatment in the pivotal study lasted a median of 9.2 months, patients remained alive, and their disease did not progress for a median of 9.3 months. 

Treanda has a chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component.  Cephalon holds exclusive rights to market and develop Treanda in the U.S.

Previous articleSome Pathogens Found to Use TLR–Induced Enzyme in Macrophages to Suppress Immunity
Next articleGTC to Receive $15M Convertible Debt Financing from LFB